Dear Editor,

Immunotherapy has become a major form of cancer therapy after chemotherapy, radiotherapy, and targeted therapy. Immune checkpoint inhibitors (ICIs), such as anti-programmed cell death 1 (PD1), anti-programmed cell death ligand 1 (PDL1), and anti-cytotoxic T-lymphocyte associated protein 4 (CTLA4), are widely studied in cancer immunotherapy.\(^1\)\(^2\) However, a considerable percentage of tumor patients fail to respond to ICI monotherapy.\(^3\)

Researchers have focused on enhancing mono-ICI efficacy through combination therapy or exploring novel immunotherapy targets. Lymphocyte-associated gene 3 (LAG3), a promising immune checkpoint, has received increasing attention recently. In this study, we described the biology of LAG3 and its function in cancer immunology, explored the multiomics characteristics of LAG3 utilizing a bioinformatics database, and provided perspective on the applications of single therapy or potential combination strategies for LAG3-targeting agents.

LAG3 is a type I transmembrane protein that can be cut by metalloproteinase to release soluble LAG3 (sLAG3). LAG3 is expressed on CD4\(^+\), CD8\(^+\), regulatory T (Treg) cell, natural killer cell, B cell, and other immune cells.\(^4\) LAG3 has been reported to play a negative regulatory role in cancer immunology by interacting with its ligands, including major histocompatibility complex II (MHC II), galectin-3, liver sinusoidal endothelial cell lectin, and fibrinogen-like protein \(^1\)\(^5\)\(^6\) (Figure 1A). For example, the LAG3–MHC II interaction can downregulate T cell proliferation and protect melanoma cells from drug-induced apoptosis.\(^7\)\(^8\) sLAG3 expression was positively correlated with dendritic cell migration and T cell antitumor ability.\(^9\)

In order to further the application of LAG3-targeting agents in cancer immunotherapy, we explored the immunomodulatory role of LAG3 in the tumor microenvironment (TME). We utilized the Gene Expression Profiling Interactive Analysis (GEPIA, http://gepia2.cancer-pku.cn) database to analyze the expression of LAG3 and other common immune checkpoints across 33 cancers (Figure 2A). The expression of lag3 in kidney renal clear cell carcinoma (KIRC), pancreatic adenocarcinoma (PAAD), skin cutaneous melanoma (SKCM), testicular germ cell tumors (TGCT), lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), and head and neck squamous cell carcinoma (HNSC) was significantly higher than in paired normal tissues, suggesting that blocking LAG3 may have a remarkable antitumor effect in these cancers. The expressions of lag3 and pdcdl1 in TGCT, lag3 and ctl4a in HNSC and PAAD, lag3, pdcdl1, and ctl4a in SKCM, and lag3, pdcdl1, cd274, and ctl4a in DLBC were significantly higher than in paired normal tissues. This provides a theoretical basis for LAG3-targeting agents in combination with other common ICIs.

We utilized the Tumor and Immune System Interaction Database (TISIDB) (http://cis.Hku.hk/TISIDB) to show the correlation between lag3 expression and tumor infiltrating lymphocyte (TIL) abundance, immunoregulatory factors, and chemokines across 30 cancer types.

Abbreviations: ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; CTLA4, cytotoxic T-lymphocyte associated protein 4; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; GEPIA, Gene Expression Profiling Interactive Analysis; HNSC, head and neck squamous cell carcinoma; ICIs, immune checkpoint inhibitors; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAG3, lymphocyte-associated gene 3; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; MHC II, major histocompatibility complex II; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PD1, programmed cell death 1; PDL1, programmed cell death ligand 1; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; sLAG3, soluble LAG3; STAD, stomach adenocarcinoma; STES, stomach and esophageal carcinoma; TCGA, The Cancer Genome Atlas; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; TIL, tumor infiltrating lymphocyte; TISIDB, Tumor and Immune System Interaction Database; TME, the tumor microenvironment; Treg, regulatory T; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
Figure 1 LAG3 biology and the mechanisms of LAG3-targeting agents. (A) LAG3 structure and its ligands. Like CD4, LAG3 consists of an extracellular, transmembrane, and an intracellular region. The interaction of LAG3 and MHC II interferes with the binding of the MHC II to CD4. LAG3 has also been reported to bind to Gal-3, LSECtin, and FGL1. LAG3 downregulates effector cell proliferation, cytokine production, and cytotoxicity by binding to its ligands. (B) The mechanisms of targeting LAG3. sLAG3 can activate APC and restore T cell function. LAG3 mAb blocks the inhibitory pathways between LAG3 and its ligands to release immune brakes. Abbreviations: APC, antigen-presenting cell; FGL1, fibrinogen-like protein 1; Gal-3, galectin-3; LAG3, lymphocyte-associated gene 3; LSECtin, liver sinusoidal endothelial cell lectin; MHC II, major histocompatibility complex II; sLAG3, soluble LAG3.

The results showed that (1) lag3 expression was correlated with the abundance of multiple TILs, such as activated CD8+ T cell, Treg cell, and myeloid-derived suppressor cell, which supports the dual negative regulatory role of LAG3 in TME. LAG3 downregulates the antitumor efficacy of effector cell and enhances the inhibitory effect of suppressor cell. (2) Lag3 expression was positively associated with other immune checkpoints, such as pdcd1 and ctla4 in multiple cancers. Similar conclusions can be drawn from the GEPIA database (Figure 3). Lag3 expression was highly correlated with pdcd1 in SKCM and kidney renal papillary cell carcinoma (KIRC), suggesting that LAG3 and PD1 cotargeted immunotherapy may induce strong synergistic antitumor properties in both cancers. (3) Lag3 expression was positively correlated with many immunostimulators, such as cd80 and cd86, suggesting that LAG3 regulates immune homeostasis together with immunostimulators. (4) Lag3 expression was positively correlated with almost all MHC-related genes, suggesting that LAG3 may interact with MHC molecules, other than MHC II. (5) Lag3 expression was positively correlated with reported chemokines and chemokine receptors, such as cxcl2, cxcl5, and ccr2. Therefore, the relationship between lag3 and chemokines needs to be further investigated.

Further correlations between lag3, pdcd1, cd274, and ctla4 expression and the clinical prognosis across 30 cancer types were analyzed utilizing TISIDB (Figure 2C). The high expression of lag3 was negatively correlated with the overall survival (OS) of KIRC, KIRP, brain lower grade glioma (LGG), and uveal melanoma (UVM) patients, suggesting that lag3 plays a pivotal role in promoting tumor growth in these tumors. The following high expressions were all negatively correlated: pdcd1 and the OS of KIRC patients, cd274 and the OS of LGG and PAAD patients, ctla4 and the OS of adrenocortical carcinoma, KIRC, KIRP, and UVM patients. We obtained similar results from the GEPIA database (Figure 2D). Interestingly, lag3 expression was positively correlated with the OS of patients with several types of tumors (Figure 2C), which is contradictory to the inhibitory role of LAG3 in the immune system. It may be due to the complicated tumor environment and different clinical features, such as the disease stage, initial treatments, and other heterogeneous factors in databases, that deserve further exploration.

There are two types of LAG3-targeting agents used as antitumor immunotherapies: LAG3 soluble dimeric recombinant protein named IMP321 and LAG3 mAb (Figure 1B). IMP321 acts as an antigen-presenting cell activator to exert an antitumor effect. LAG3 mAb blocks the binding
of LAG3 and its ligands to improve the antitumor activity of the host, which is widely applied in drug discovery. Dozens of IMP321 and LAG3 mAb-related clinical trials for various cancers are currently underway, most of which are combined with anti-PD1 (Table 1). LAG3 and PD1 / PDL1 / CTLA4 bispecific antibody immunotherapy is also in progress (Table S1).

ICIs have greatly benefited tumor patients, and combination therapy improved the efficacy of ICIs. LAG3 is a promising checkpoint that negatively regulates T cell activation and indicates a poor prognosis for KIRC, KIRP, and many other tumors. The single application of LAG3-targeting agents in the dominant population and in combination with other ICIs, such as anti-PD1 / PDL1 / CTLA4, is expected to benefit more tumor patients. We hope that more clinical trials of LAG3-targeting agents in combination with chemotherapy, radiotherapy, and targeted therapy could be performed to obtain encouraging results.

ACKNOWLEDGMENTS
The authors would like to sincerely thank the open-access databases for data sharing and processing.

FIGURE 2  Multiomics analysis of LAG3 and other common immune checkpoints in a Pan-cancer analysis. (A) Lag3 and pdc1 / cd274 / cta4 expression profiles across all tumor samples and paired normal tissues. Each dot represents a distinct tumor or normal sample. Red text of each cancer type indicates that the gene is overexpressed in tumors than in normal tissues. Green text of each cancer type indicates that the gene is underexpressed in tumors than in normal tissues. Four-way analysis of variance, using sex, age, ethnicity, and disease state (tumor or normal) as variables was applied to calculate differential expression. The expression data were log2 (TPM + 1) transformed. p < 0.01 was considered statistically significant. (B) Spearman’s correlation of lag3 with immune features across multiple cancers. p < 0.05 was considered statistically significant. (C) Association analyses between lag3 / pdc1 / cd274 / cta4 and clinical prognosis across multiple cancers. Red bars signify that high levels of the molecule are significantly associated with longer OS. Blue bars signify that high levels of the molecule are significantly associated with decreased OS. A log rank test was used to calculate the associations. (D) The survival heatmap shows the prognostic impact of lag3 / pdc1 / cd274 / cta4. With an increase in gene expression, the red and blue blocks denote high and low risks, respectively. The rectangles with frames indicate the significant unfavorable and favorable results in prognostic analyses. Mantel–Cox test was used to compare the survival contribution of these genes. p < 0.05 was considered statistically significant. Abbreviations: CTLA4, cytotoxic T-lymphocyte associated protein 4; LAG3, lymphocyte-associated gene 3; PDCD1, programmed cell death 1
Correlation analysis between $\text{lag3}$ and $\text{pdcdl} / \text{cd274} / \text{ctla4}$ across multiple cancers. Each dot represents a distinct tumor or normal sample. The non-log scale was used for calculation and the log-scale axis was used for visualization. Pearson test was used to analyze the correlation between $\text{lag3}$ and $\text{pdcdl} / \text{cd274} / \text{ctla4}$. $p < 0.05$ was considered statistically significant.
**TABLE 1  Clinical studies of LAG3 single-targeted immunotherapy**

| Drugs            | NCT ID     | Tumor types                  | Phase | Number enrolled | Combination agents (targeting LAG3 drugs + X) | Status            |
|------------------|------------|------------------------------|-------|-----------------|-----------------------------------------------|-------------------|
| **Soluble LAG3 Ig** |            |                              |       |                 |                                               |                   |
| IMP321           | NCT03252938 | Solid tumors                 | I     | 50              | Avelumab                                      | Recruiting        |
|                  | NCT03625323 | NSCLC, SCCHN                 | II    | 109             | Pembrolizumab                                 | Recruiting        |
|                  | NCT00351949 | Advanced RCC                 | I     | 24              | –                                             | Completed         |
|                  | NCT02676869 | Stage III/IV melanoma        | I     | 24              | Pembrolizumab                                 | Completed         |
|                  | NCT02614833 | Adenocarcinoma breast stage IV | II    | 241             | Paclitaxel                                    | Active, not recruiting |
|                  | NCT00349934 | Metastatic breast cancer     | I     | 33              | Paclitaxel                                    | Completed         |
| **Anti-LAG3 mAb** |            |                              |       |                 |                                               |                   |
| BMS986016 Relatlimab | NCT02966548 | Advanced solid tumors        | I     | 45              | Nivolumab                                     | Active, not recruiting |
|                  | NCT02061761 | Hematologic neoplasms        | I/II  | 109             | Nivolumab                                     | Active, not recruiting |
|                  | NCT03743766 | Melanoma                     | II    | 42              | Nivolumab                                     | Recruiting        |
|                  | NCT01968109 | Neoplasms by site            | I/II  | 1500            | Nivolumab, BMS-986213                         | Recruiting        |
|                  | NCT03623854 | Chordoma                     | II    | 20              | Nivolumab                                     | Recruiting        |
|                  | NCT03493932 | Glioblastoma                 | I     | 25              | Nivolumab                                     | Recruiting        |
|                  | NCT03642067 | Colorectal adenocarcinoma    | II    | 64              | Nivolumab                                     | Recruiting        |
|                  | NCT03459222 | Advanced cancer              | I/II  | 230             | Nivolumab, Ipilimumab, BMS986205              | Recruiting        |
|                  | NCT04326257 | SCCNH                        | II    | 40              | Nivolumab, Ipilimumab                         | Recruiting        |
|                  | NCT03607890 | Refractory MSI - H solid tumors prior of PD-L1 therapy | II    | 21              | Nivolumab                                     | Recruiting        |
|                  | NCT02488759 | Advanced cancer              | I/II  | 584             | Nivolumab, Ipilimumab, Daratumumab            | Active, not recruiting |
|                  | NCT02658981 | Gliosarcoma                  | I     | 100             | Nivolumab                                     | Recruiting        |
|                  | NCT02996110 | Advanced cancer              | II    | 200             | Nivolumab, Ipilimumab                         | Recruiting        |
|                  | NCT02750514 | Advanced cancer              | II    | 504             | Dasatinib, Nivolumab                          | Active, not recruiting |
|                  | NCT02060188 | Microsatellite unstable colorectal cancer | II    | 340             | Nivolumab, Ipilimumab, Cobiimetinib           | Recruiting        |
|                  | NCT04080804 | SCCHN                        | II    | 60              | Nivolumab, Ipilimumab                         | Recruiting        |
|                  | NCT02935634 | Advanced gastric cancer      | II    | 600             | Nivolumab, Ipilimumab                         | Recruiting        |
|                  | NCT02519322 | Cutaneous melanoma           | II    | 53              | Nivolumab, Ipilimumab                         | Recruiting        |
|                  | NCT03044613 | Gastric cancer               | I     | 25              | Carboplatin, Nivolumab                        | Recruiting        |
|                  | NCT04062656 | Gastric cancer               | II    | 88              | Nivolumab, Ipilimumab                         | Recruiting        |
|                  | NCT03335540 | Advanced cancer              | I     | 50              | Cabiralizumab, Nivolumab                      | Recruiting        |
| **LAG525**       | NCT03499899 | Triple negative breast cancer | II    | 88              | Spartalizumab                                 | Active, not recruiting |
|                  | NCT03365791 | Advanced solid and hematologic malignancies | II    | 76              | PDR001                                       | Active, not recruiting |

Abbreviations: LAG3, lymphocyte-associated gene 3; NSCLC, non-small cell lung cancer; PDL1, programmed cell death ligand 1; RCC, renal cell carcinoma; SCCHN, head and neck squamous cell carcinoma.
COMPETING INTERESTS
The authors declare that they have no competing interests.

AUTHORS CONTRIBUTION
Q.L. contributed to the design of the review and revised the article, had full access to all the contents included in this study, and took responsibility for the integrity of the data and the accuracy of the data analysis. M.W. and J.J. collected the literature. M.W. performed the bioinformatics analysis, prepared the figures, and performed the data interpretation. M.W., Q.D., Y.W., and Y.L. wrote the main manuscript text. All the authors contributed to the review and revision of the manuscript, and all authors read and approved the final manuscript.

AVAILABILITY OF DATA AND MATERIALS
All data generated or analyzed during this study are included.

CONSENT FOR PUBLICATION
All authors approved the final manuscript for publication.

FUNDING
This work was supported by the Research Foundation of Beijing Friendship Hospital, Capital Medical University (No. yyqdky2019-40 and No. yyzscq202003).

Correspondence
Dr. Qin Li, Department of Oncology, Beijing Friendship Hospital, 95 Yongan Road, Beijing 100050, China.
Email: qinli128003@ccmu.edu.cn

ORCID
Qin Li https://orcid.org/0000-0002-2470-6089

REFERENCES
1. Wilky BA. Immune checkpoint inhibitors: the linchpins of modern immunotherapy. *Immunol Rev*. 2019;290:6-23.
2. Kon E, Benhar I. Immune checkpoint inhibitor combinations: current efforts and important aspects for success. *Drug Resist Updat*. 2019;45:13-29.
3. Burugu S, Dancsok AR, Nielsen TO. Emerging targets in cancer immunotherapy. *Semin Cancer Biol*. 2018;52:39-52.
4. Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. LAG-3: from molecular functions to clinical applications. *J Immunother Cancer*. 2020;8:e001034.
5. Wang J, Sanmamed MF, Datar I, et al. Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. *Cell*. 2019;176:334–347.
6. Qin S, Xu L, Yi M, et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. *Mol Cancer*. 2019;18:155.
7. Hemon P, Jean-Louis F, Ramgolam K, et al. MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis. *J Immunol*. 2011;186:5173-5183.
8. Maruhashi T, Okazaki I-M, Sugiura D, et al. LAG-3 inhibits the activation of CD4 T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII. *Nat Immunol*. 2018;19:1415-1426.
9. Andrews LP, Marciscano AE, Drake CG, Vignali DA. LAG3 (CD223) as a cancer immunotherapy target. *Immunol Rev*. 2017;276:80-96.
10. Kok M. LAG-3: another brake to release in breast cancer? *Ann Oncol*. 2017;28:2907-2908.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.